AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04540185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: oral polio vaccine
Description: Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump
Study NCT04540185 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparable Placebo
Description: Placebo of a vaccine 0.1 ml administered orally on a sugar lump
Study NCT04540185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NA-831
Description: Drug: NA-831 30 mg of NA-831 in a capsule administered orally
Study NCT04540185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparable Placebo of drug
Description: Placebo 30 mg in a capsule administered orally
Study NCT04540185 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination of oral polio vaccine and NA-831
Description: Combination of biological: Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump and drug NA-831 30 mg in a capsule administered orally
Study NCT04540185 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Comparable Placebo of Oral Polio Vaccine and Placebo of drug
Description: Combination of biological placebo 0.1 ml administered orally on a sugar lump and drug placebo 30 mg in a capsule administered orally
Study NCT01283841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil 500 mg tablets
Study NCT01283841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil 500 mg tablets
Study NCT02039115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 6 weeks of prednisone and placebo therapy will be given over 6 weeks after both the first and second stage complete Barretts Excision.
Study NCT02039115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 6 weeks of placebo therapy will be given in the same manner as the prednisone arm after the first and second stage complete Barretts excision.
Study NCT01194830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: Active drug 1 tablet PO QD
Study NCT01194830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 Tablet PO QD
Study NCT05357625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback Informed Treatment
Description: FIT is based on two simple questionnaires and aims to assess and improve the effectiveness of therapeutic treatment. Treatment outcomes are assessed with the Outcome Rating Scale (ORS), a four-item self-report instrument measuring client functioning in the area of quality of life. Therapeutic alliance is assessed using the four-item Session Rating Scale (SRS). In FIT the feedback from the client is used to continuous adjustment and improvement of therapy
Study NCT03793751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine Injection
Description: Dexmedetomidine Injection at a dose of 1 mcg/kg over 10 min, after Spinal Anaesthesia and before start of surgery, followed by a continuous infusion at a rate of 0.4 mcg/kg/h until the end of surgery.
Study NCT03793751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection
Description: Dexmedetomidine Injection at a dose of 1 mcg/kg over 10 min, after Spinal Anaesthesia and before start of surgery, followed by a continuous infusion at a rate of 0.4 mcg/kg/h until the end of surgery.
Study NCT04364386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InPress Device
Description: Treatment with InPress Device for Postpartum Hemorrhage
Study NCT04489316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Narrative medicine curriculum
Description: The curriculum will consist of three sessions in narrative medicine- i.e. discussing texts and poetry, and engaging in reflective writing as a group
Study NCT05131945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Suction Thoracentesis
Description: a procedure that removes excess fluid from the space in between your lungs and chest wall
Study NCT05131945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gravity Thoracentesis
Description: a procedure that removes excess fluid from the space in between your lungs and chest wall
Study NCT02439853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly Check-in Session
Description: Subjects in the Check-In group will have an online session with a speech-language pathologist 3-, 4-, and 5-months from the subject's enrollment date.
Study NCT01705119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standing
Study NCT03035032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Subcutaneous Injection
Study NCT01183260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trabecular Metal Revision Cup
Description: Revision of the acetabular cup
Study NCT01183260 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trabecular Metal Modular Cup
Description: Revision of the acetabular cup
Study NCT03716180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug
Study NCT03716180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab works by targeting the HER2/neu receptor on cancer cells
Study NCT03716180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab is a monoclonal antibody which targets the surface of the cells human epidermal growth factor receptor 2 protein (HER2) on the cancer cell, interfering with HER2 causing cancer cell death
Study NCT00746681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine & Pregabalin
Description: Tolterodine SR Oral, 2mg, once daily for 4 weeks Pregabalin, Oral, 75 mg, twice daily for 4 weeks
Study NCT00746681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Description: Tolterodine SR, Oral, 4 mg, once daily for 4 weeks
Study NCT00746681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, Oral, twice daily for 4 weeks
Study NCT00746681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine & Pregabalin
Description: Tolterodine SR Oral, 4mg, once daily for 4 weeks Pregabalin, Oral, 150 mg, twice daily for 4 weeks
Study NCT00746681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin, Oral, 150 mg twice daily for 4 weeks
Study NCT01953640 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01953640 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03864783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin (Meriva®)
Description: Experimental drug:~Meriva® 500 mg tablet (contains 1 mg curcumin)
Study NCT03864783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo:~Contains same ingredients as Meriva®, apart from curcumin. Similar in appearance to Meriva®.
Study NCT04040764 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tritanium uncemented Total Knee Replacement
Description: This will be an internal pilot study in which patients will be blinded and randomly assigned to 1 of 2 arms with 30 patients in each arm. The first arm will receive a Triathlon knee replacement device which is cemented into place. The second arm will receive an uncemented Triathlon Tritanium TKR.
Study NCT04040764 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tritanium uncemented Total Knee Replacement
Description: This will be an internal pilot study in which patients will be blinded and randomly assigned to 1 of 2 arms with 30 patients in each arm. The first arm will receive a Triathlon knee replacement device which is cemented into place. The second arm will receive an uncemented Triathlon Tritanium TKR.
Study NCT03381690 — intervention group
Intervention type: PROCEDURE
Intervention: Epidural labor analgesia
Description: Epidural catheter was inserted for labor analgesia using an 18-gauge Tuohy needle and a 20 gauge epidural catheter. In our institute, for epidural labor analgesia, 10 ml bolus of 0.075% levobupivacaine mixed with fentanyl 2 μg/ml was administered and same regimen was continuously infused by patient-controlled epidural analgesia (infusion rate : 10 ml/hr, bolus : 4 ml, lockout time: 30 min).
Study NCT04043910 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fNIRS
Description: The auditory cortical imaging will be performed by fNIRS measures. This non-invasive functional imaging technique relies on the use of a sensor-bearing cap, measuring cortical activity through scalp, during auditory stimulation. As head movement does not alter measurement that much, fNIRS is well adapted to children.
Study NCT04043910 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fNIRS
Description: The auditory cortical imaging will be performed by fNIRS measures. This non-invasive functional imaging technique relies on the use of a sensor-bearing cap, measuring cortical activity through scalp, during auditory stimulation. As head movement does not alter measurement that much, fNIRS is well adapted to children.
Study NCT04043910 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Speech intelligibility
Description: Speech intelligibility will be evaluated with French sentences comprehension in noise, from the Common Test or Adaptive Auditive Speech Test before 6 years, from the Common Test or Hearing in Noise Test for Children (Hint-C) from 7 to 11 years, and from the Hint-C or Marginal Benefit of Acoustic Amplification after 11 years, both with a Signal over Noise Ratio of +10 decibel at 65 decibel
Study NCT04043910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech intelligibility
Description: Speech intelligibility will be evaluated with French sentences comprehension in noise, from the Common Test or Adaptive Auditive Speech Test before 6 years, from the Common Test or Hearing in Noise Test for Children (Hint-C) from 7 to 11 years, and from the Hint-C or Marginal Benefit of Acoustic Amplification after 11 years, both with a Signal over Noise Ratio of +10 decibel at 65 decibel
Study NCT04043910 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sound localisation
Description: Sound localisation will be evaluated with a left-right discrimination test before 7 years and a 12 loudspeakers sound localisation test after 7 years.
Study NCT04043910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sound localisation
Description: Sound localisation will be evaluated with a left-right discrimination test before 7 years and a 12 loudspeakers sound localisation test after 7 years.
Study NCT04043910 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Speech assessments
Description: Speech assessments will be performed by dedicated speech therapists, with child age specific tests, and 2 global speech scores: the Category of Auditory Performances scale - second edition, and the Speech Intelligibility Rating scale.
Study NCT04043910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech assessments
Description: Speech assessments will be performed by dedicated speech therapists, with child age specific tests, and 2 global speech scores: the Category of Auditory Performances scale - second edition, and the Speech Intelligibility Rating scale.
Study NCT04043910 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life
Description: Quality of Life (QoL) evaluation will be based on the generic QoL scale, and the Speech Spatial and Qualities of hearing (SSQ) deafness specific scale. Each scale exists in age specific modalities.
Study NCT04043910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life
Description: Quality of Life (QoL) evaluation will be based on the generic QoL scale, and the Speech Spatial and Qualities of hearing (SSQ) deafness specific scale. Each scale exists in age specific modalities.
Study NCT02678949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Fluticasone 50 mcg/twice day
Description: After 7 days washout period, patients with mild asthma (group 2) will come to visit 2 where carried out a baseline spirometry and MBW test, subsequently will indicate them start treatment with inhaled fluticasone 50 mcg/twice a day, for a period of 4 weeks. At the end of the 4 weeks of treatment patients will come to Visit 3 and perform again spirometry and MBW test.
Study NCT02678949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Fluticasone 100 mcg/twice day
Description: After 7 days washout period, patients with moderate asthma (group 3) will come to visit 2 where carried out a baseline spirometry and MBW test, subsequently will indicate them start treatment with inhaled fluticasone of 100 mcg/twice a day, for 4 weeks period. At the end of the 4 weeks of treatment patients will come to Visit 3 and perform again spirometry and MBW test.
Study NCT02678949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Albuterol
Description: The patients in Group 2 and group 3 performing a baseline spirometry and MBW test, after which one dose of 400 mcg of inhaled albuterol will be administered. Twenty minutes after inhaling the dose of albuterol, spirometry and MBW test will be measured again in both groups.
Study NCT03603782 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2.5% protein
Description: 2.5%
Study NCT03603782 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein 5%
Description: 5%
Study NCT03603782 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein 10%
Description: 10%
Study NCT03603782 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein 15%
Description: 15%
Study NCT03603782 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A2: Peptamen 1.5 Vanilla without Breakfast
Description: Peptamen withoug breakfast
Study NCT03603782 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B2: only breakfast (no product)
Description: only breakfast
Study NCT03603782 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: C2: 5% protein with breakfast
Description: C2: 5% protein consumed with breakfast
Study NCT03603782 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D2: 5% protein 30 min before breakfast
Description: D2: 5% protein consumed 30 min before breakfast
Study NCT03787056 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood draws
Description: Blood draws are realized at each steps of patient disease management. The volume of each blood drawn is 25 mL for progastrin measurements and 5 mL for the dosage of the other tumor markers. The frequency depend to the cancer and treatment administered :~* Baseline at diagnosis : Local radical treatment : within 24h before surgery, within 24h after surgery and at the post-surgery follow up visit~* Chemotherapy treatment : every 3 or 4 weeks~* Radiotherapy : start day and at the end of radiation (end of treatment visit)~* Palliative systemic treatment (only palliative cohorts) : every 3 to 12 weeks. Follow until the third progression or change of treatment line, or alternatively up to 5 years after inclusion~* In case of PD or TOX~* Follow up: at each visit scheduled (every 3 months) for the first 2 years, then every 6 months for 3 years~* Relapse : withdrawn from the study and last progastrin measurement. Patient could be enrolled in the non-curative intent cohort
Study NCT00306670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxan
Description: Acquired Hemophilia A Patients Who Have Developed Anti-Factor VIII Antibodies
Study NCT00306670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: \<30 mg/day
Study NCT00306670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: \<30 mg/day
Study NCT05871567 — intervention group
Intervention type: PROCEDURE
Intervention: colorectal resection
Description: potential resective surgery
Study NCT03454698 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Usual care as described for the CG also applies to the IG. The intervention will consist of giving patients an opportunity to learn about the use of compression bandages, wearing and putting on compression stockings, physical activity, good skin care, and a high-protein, vitamin-rich diet. This group will be supervised by a study nurse, who will not be identical with the nurse in charge of the control group.
Study NCT01827475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: single dose
Study NCT01827475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: single dose
Study NCT01827475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen-acetaminophen combination
Description: single dose
Study NCT04049734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral losatan
Description: 50 mg of oral losartan one hour before the ERCP once
Study NCT00159133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antipsychotics vs. Lorazepam (Drugs)
Description: Early intervention with low-dose antipsychotics vs. lorazepam (up to 3 mg/day) in case of early warning signs of an impending relapse;
Study NCT00159133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antipsychotics vs. Lorazepam (Drugs)
Description: Early intervention with low-dose antipsychotics vs. lorazepam (up to 3 mg/day) in case of early warning signs of an impending relapse;
Study NCT04369859 — intervention group
Intervention type: BEHAVIORAL
Intervention: Examine the impact of COVID-19 during pregnancy
Description: clinical data collection
Study NCT02112032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: This is a dose escalation study to determine the serious and non-serious adverse events that occur as the dose increases.
Study NCT02112032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: This is a dose escalation study to determine the serious and non-serious adverse events that occur from the combination of Peginterferon and MK-3475 as the doses increase.
Study NCT01703650 — intervention group
Intervention type: DRUG
Intervention: iopromide
Description: 1. iopromide (370mgI/mL) enhanced perfusion CT will be performed within 14 days of operation.~2. In patients who are planned to receive chemotherapy, iopromide enhanced perfusion CT was performed twice; within 14 days before starting 1st cycle and within 14 days after finishing 2nd cycle.~3. iopromide (370mgI/mL) will be administered intravenously with an amount of 30mL (body weight\[BW\] \<50kg) or 35 mL (50kg ≤BW \<70kg) or 40 mL (70 kg≤BW \<90kg) or 50 mL (90≤BW), followed by saline infusion (30mL).~4. Injection rate is as follows; 6.0mL/sec if BW is \<50kg, 7.0 mL/sec if BW is 50kg≤and \<70kg, 8.0 mL/sec if BW is 70≤and\<90kg and 9.0mL/sec if BW is 90kg≤.
Study NCT01703650 — intervention group
Intervention type: PROCEDURE
Intervention: CT
Description: 1. Perfusion CT will be performed by using a 320 channel MDCT~2. Patients are requested for fasting for at least 8 hours before CT scan.~3. Patients are requested for doing shallow breathing as slow as possible and wide strap is applied during CT scan.~4. Scan range is limited to the whole pancreas and it focuses to the pancreas tumor lesion.~5. During perfusion CT, 19 phases (ten phases with two seconds interval and six phases with three seconds interval and three phases with five seconds interval) are obtained in fifty three seconds.~6. ADIR 3D and SURE EXPOSURE 3D are applied during perfusion CT to minimize radiation dose.
Study NCT03484845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin and ferrous fumarate
Description: * Group 1:include 50 women will receive oral lactoferrin 100mg twice daily .~* Group 2: include 50 women will receive oral Ferrous fumarate 30mg elemental iron twice daily .~* Group 3: include 50 women will receive oral combined lactoferrin 200mg and ferrous fumarate 60mg elemental iron once daily .
Study NCT03029351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide Extended Release for Inj Susp 2 MG
Description: Exenatide extended release treatment weekly for 1 year in T2DM patients with micro- and macroalbuminuria
Study NCT03029351 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo treatment weekly for 1 year in type 2 diabetes with micro-and macroalbuminuria
Study NCT04027192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2328065 LSF
Description: 20 mg/mL LSF (liquid service formulation), orally
Study NCT01824238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anacetrapib
Study NCT01824238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for anacetrapib
Study NCT03243695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Angled Abutment
Description: virtual implants will be placed on a planning software allowing abutments to be placed at an angle to the implant. Teeth will be extracted at the surgery using periotome and implants will be placed using computer aided surgical guide. The angled abutment will be placed and a temporary crown material will be fabricated.
Study NCT03243695 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: straight abutment
Description: virtual implants will be placed on a planning software allowing abutments to be placed at straight to the implant. Teeth will be extracted at the surgery using periotome and implants will be placed using computer aided surgical guide. The straight abutment will be placed and a temporary crown material will be fabricated.